Latest Pharma Insights
Biogen Justifies Phase III Trial For Anti-Tau Drug Despite Phase II Miss
The Phase II trial of diranersen (BIIB080) failed on the dose response primary endpoint, but Biogen believes tau reductions, a slowing in cognitive decline and acceptable safety justify a Phase III program.
Scrip - May 14, 2026
The Phase II trial of diranersen (BIIB080) failed on the dose response primary endpoint, but Biogen believes tau reductions, a slowing in cognitive decline and acceptable safety justify a Phase III program.
Scrip - May 14, 2026
PCPC Urges FDA On MoCRA, Innovation After Makary Exit
PCPC said it appreciates former FDA Commissioner Marty Makary’s leadership during a ‘pivotal’ time for innovation and looks forward to working with Acting Commissioner Kyle Diamantas.
HBW Insight - May 14, 2026
PCPC said it appreciates former FDA Commissioner Marty Makary’s leadership during a ‘pivotal’ time for innovation and looks forward to working with Acting Commissioner Kyle Diamantas.
HBW Insight - May 14, 2026
Industry Grappling With Fallout From MFN And What’s Next
The US government’s most favored nation drug pricing agreement ushers in challenges and opportunities; panelists at the Financial Times US Pharma & Biotech Summit weighed in.
Scrip - May 14, 2026
The US government’s most favored nation drug pricing agreement ushers in challenges and opportunities; panelists at the Financial Times US Pharma & Biotech Summit weighed in.
Scrip - May 14, 2026
BeOne Is Number Two In BCL2 Inhibitor Market With Beqalzi Approval
The FDA approved Beqalzi for later-line mantle cell lymphoma, and with multiple Phase III trials in chronic lymphocytic leukemia, the biotech is setting the drug up as a competitor to Venclexta.
Scrip - May 14, 2026
The FDA approved Beqalzi for later-line mantle cell lymphoma, and with multiple Phase III trials in chronic lymphocytic leukemia, the biotech is setting the drug up as a competitor to Venclexta.
Scrip - May 14, 2026
Finance Watch: AI Firm Isomorphic Raises $2.1bn One Year After $600m Series A Round
Private Company Edition: Isomorphic Labs, an artificial intelligence-enabled drug designer and developer, revealed its second round of external funding since its founding in 2021. And in its Q1 financing report, Biomedtracker shows a $1.77bn year-over-year rise in biopharma VC fundraising.
Scrip - May 14, 2026
Private Company Edition: Isomorphic Labs, an artificial intelligence-enabled drug designer and developer, revealed its second round of external funding since its founding in 2021. And in its Q1 financing report, Biomedtracker shows a $1.77bn year-over-year rise in biopharma VC fundraising.
Scrip - May 14, 2026
Medicare, Medicaid Patients Could Face Higher Costs From Rx-To-OTC Switches
Rx-to-OTC switches could raise out-of-pocket costs for Medicare and Medicaid patients if coverage policies do not adjust accordingly.
HBW Insight - May 14, 2026
Rx-to-OTC switches could raise out-of-pocket costs for Medicare and Medicaid patients if coverage policies do not adjust accordingly.
HBW Insight - May 14, 2026
Karo Builds In APAC With Moberg’s Nail Fungus Innovation
Karo Healthcare has snapped up the exclusive rights to market Moberg Pharma’s topical onychomycosis treatment, MOB-15, under its Lamisil brand in four markets across Asia Pacific.
HBW Insight - May 14, 2026
Karo Healthcare has snapped up the exclusive rights to market Moberg Pharma’s topical onychomycosis treatment, MOB-15, under its Lamisil brand in four markets across Asia Pacific.
HBW Insight - May 14, 2026
Making Robotic Surgery Affordable Is Florida Company’s ‘Mantra’
SS Innovations is confident that the track record of its Mantra robotic system will result in an FDA clearance sometime this year. The company is also seeking the CE mark for Mantra, which has already been cleared for use in 11 countries. The company’s CEO discusses the robotic system.
Medtech Insight - May 14, 2026
SS Innovations is confident that the track record of its Mantra robotic system will result in an FDA clearance sometime this year. The company is also seeking the CE mark for Mantra, which has already been cleared for use in 11 countries. The company’s CEO discusses the robotic system.
Medtech Insight - May 14, 2026
EU Details AI Act Medtech Compromise
New AI Act text mandates the European Commission to reduce regulatory burden, but bottlenecks are still expected.
Medtech Insight - May 14, 2026
New AI Act text mandates the European Commission to reduce regulatory burden, but bottlenecks are still expected.
Medtech Insight - May 14, 2026
Imfinzi Floats To Third Bladder Cancer Win On VOLGA
AstraZeneca has chalked up another Phase III success for Imfinzi in bladder cancer, an indication that is regarded as a key growth area for the megablockbuster immunotherapy.
Scrip - May 14, 2026
AstraZeneca has chalked up another Phase III success for Imfinzi in bladder cancer, an indication that is regarded as a key growth area for the megablockbuster immunotherapy.
Scrip - May 14, 2026
Valneva Axes Up To 15% Of Its Workforce As Travel Vaccine Demand Falls
The French vaccine maker is scaling back operations and cutting its workforce in an effort to save cash and turn focus back to its proprietary products.
Scrip - May 14, 2026
The French vaccine maker is scaling back operations and cutting its workforce in an effort to save cash and turn focus back to its proprietary products.
Scrip - May 14, 2026
Cipla Navigates West Asia Strain, Bets On US Momentum
Cipla is cushioning the impact of the Middle East crisis via inventory management and resources on hand and also leaning on momentum in its US business, with products like generic Ventolin lined up for launch, to drive growth.
Scrip - May 14, 2026
Cipla is cushioning the impact of the Middle East crisis via inventory management and resources on hand and also leaning on momentum in its US business, with products like generic Ventolin lined up for launch, to drive growth.
Scrip - May 14, 2026
Mylan Epoprostenol Win Clarifies US Measurement Rules And Equivalents Limits
Viatris’ Mylan has prevailed at the Federal Circuit after the court held Actelion’s Veletri formulation claims required pH measurement at standard temperature, while the claims could not be saved through the doctrine of equivalents.
Generics Bulletin - May 14, 2026
Viatris’ Mylan has prevailed at the Federal Circuit after the court held Actelion’s Veletri formulation claims required pH measurement at standard temperature, while the claims could not be saved through the doctrine of equivalents.
Generics Bulletin - May 14, 2026
The Generics Bulletin Podcast: Biosimilars Conference Report And Big M&A Deals
Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, as well as talking about the latest big deals in biosimilars and what is behind them.
Generics Bulletin - May 14, 2026
Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, as well as talking about the latest big deals in biosimilars and what is behind them.
Generics Bulletin - May 14, 2026
Medtech’s Hottest Turf War: Why Every Medtech Giant Wants A Piece Of The IVL Market
Intravascular lithotripsy spent years as Shockwave's niche. With J&J's acquisition complete and rivals closing in, the market for cracking arterial calcium is about to get competitive.
In Vivo - May 14, 2026
Intravascular lithotripsy spent years as Shockwave's niche. With J&J's acquisition complete and rivals closing in, the market for cracking arterial calcium is about to get competitive.
In Vivo - May 14, 2026
Dealmaking Quarterly Statistics, Q1 2026
During Q1, biopharma merger and acquisition deal value reached $54bn and drew in $88.7bn in potential deal value from alliances. Device company M&A values reached $27bn, while in vitro diagnostics and research tools players’ M&A activity totaled $986m.
In Vivo - May 14, 2026
During Q1, biopharma merger and acquisition deal value reached $54bn and drew in $88.7bn in potential deal value from alliances. Device company M&A values reached $27bn, while in vitro diagnostics and research tools players’ M&A activity totaled $986m.
In Vivo - May 14, 2026
Fosun, AriBio’s Alzheimer’s Partnership Expands To Global Markets Via Option Deal
Fosun Pharma moves to expand partnership with AriBio to major global markets for the Korean biotech’s oral Alzheimer's candidate AR100, amid anticipated topline Phase III results in 2026.
Scrip - May 14, 2026
Fosun Pharma moves to expand partnership with AriBio to major global markets for the Korean biotech’s oral Alzheimer's candidate AR100, amid anticipated topline Phase III results in 2026.
Scrip - May 14, 2026
FDA Issues Final Guidance For Patient-Matched Orthopedic Surgical Guides
The final guidance sets out testing, documentation and design process expectations for devices shaped from patient imaging to position orthopedic implants but leaves key thresholds for industry to interpret.
Medtech Insight - May 14, 2026
The final guidance sets out testing, documentation and design process expectations for devices shaped from patient imaging to position orthopedic implants but leaves key thresholds for industry to interpret.
Medtech Insight - May 14, 2026
MSD Expands R&D Collabs With Multiple Chinese Firms
MSD leverages its China R&D collaboration platform to discover early R&D programs with high potential from Chinese companies to speed up clinical translation and clinical development.
Scrip - May 14, 2026
MSD leverages its China R&D collaboration platform to discover early R&D programs with high potential from Chinese companies to speed up clinical translation and clinical development.
Scrip - May 14, 2026
AstraZeneca Joins Pharma’s Agentic AI Race With Three-Year Owkin Deal
Owkin will build custom agents on its K Pro platform to track rival trials, forecast outcomes and scan patents for AstraZeneca — extending a partnership that already produced a BRCA prescreening tool.
Medtech Insight - May 14, 2026
Owkin will build custom agents on its K Pro platform to track rival trials, forecast outcomes and scan patents for AstraZeneca — extending a partnership that already produced a BRCA prescreening tool.
Medtech Insight - May 14, 2026
Shionogi Eyes Growth From Radicava, Torii Business This Fiscal Year
Japanese firm eyes 40% revenue growth this fiscal year, boosted by acquisitions of Torii and Radicava, despite a big slowdown for its oral COVID-19 antiviral.
Scrip - May 14, 2026
Japanese firm eyes 40% revenue growth this fiscal year, boosted by acquisitions of Torii and Radicava, despite a big slowdown for its oral COVID-19 antiviral.
Scrip - May 14, 2026
Makary Leaves OTC Mark As FDA Commissioner But One Consumer Health Blank Space Resonates
Martin Makary established himself after becoming commissioner in March 2025 as an ally for OTC drug providers by saying on multiple occasions that more drugs should be available nonprescription.
HBW Insight - May 14, 2026
Martin Makary established himself after becoming commissioner in March 2025 as an ally for OTC drug providers by saying on multiple occasions that more drugs should be available nonprescription.
HBW Insight - May 14, 2026
Biogen Justifies Phase III Trial For Anti-Tau Drug Despite Phase II Miss
The Phase II trial of diranersen (BIIB080) failed on the dose response primary endpoint, but Biogen believes tau reductions, a slowing in cognitive decline and acceptable safety justify a Phase III program.
Scrip - May 14, 2026
The Phase II trial of diranersen (BIIB080) failed on the dose response primary endpoint, but Biogen believes tau reductions, a slowing in cognitive decline and acceptable safety justify a Phase III program.
Scrip - May 14, 2026
Industry Grappling With Fallout From MFN And What’s Next
The US government’s most favored nation drug pricing agreement ushers in challenges and opportunities; panelists at the Financial Times US Pharma & Biotech Summit weighed in.
Scrip - May 14, 2026
The US government’s most favored nation drug pricing agreement ushers in challenges and opportunities; panelists at the Financial Times US Pharma & Biotech Summit weighed in.
Scrip - May 14, 2026
BeOne Is Number Two In BCL2 Inhibitor Market With Beqalzi Approval
The FDA approved Beqalzi for later-line mantle cell lymphoma, and with multiple Phase III trials in chronic lymphocytic leukemia, the biotech is setting the drug up as a competitor to Venclexta.
Scrip - May 14, 2026
The FDA approved Beqalzi for later-line mantle cell lymphoma, and with multiple Phase III trials in chronic lymphocytic leukemia, the biotech is setting the drug up as a competitor to Venclexta.
Scrip - May 14, 2026
Finance Watch: AI Firm Isomorphic Raises $2.1bn One Year After $600m Series A Round
Private Company Edition: Isomorphic Labs, an artificial intelligence-enabled drug designer and developer, revealed its second round of external funding since its founding in 2021. And in its Q1 financing report, Biomedtracker shows a $1.77bn year-over-year rise in biopharma VC fundraising.
Scrip - May 14, 2026
Private Company Edition: Isomorphic Labs, an artificial intelligence-enabled drug designer and developer, revealed its second round of external funding since its founding in 2021. And in its Q1 financing report, Biomedtracker shows a $1.77bn year-over-year rise in biopharma VC fundraising.
Scrip - May 14, 2026
Imfinzi Floats To Third Bladder Cancer Win On VOLGA
AstraZeneca has chalked up another Phase III success for Imfinzi in bladder cancer, an indication that is regarded as a key growth area for the megablockbuster immunotherapy.
Scrip - May 14, 2026
AstraZeneca has chalked up another Phase III success for Imfinzi in bladder cancer, an indication that is regarded as a key growth area for the megablockbuster immunotherapy.
Scrip - May 14, 2026
Valneva Axes Up To 15% Of Its Workforce As Travel Vaccine Demand Falls
The French vaccine maker is scaling back operations and cutting its workforce in an effort to save cash and turn focus back to its proprietary products.
Scrip - May 14, 2026
The French vaccine maker is scaling back operations and cutting its workforce in an effort to save cash and turn focus back to its proprietary products.
Scrip - May 14, 2026
Cipla Navigates West Asia Strain, Bets On US Momentum
Cipla is cushioning the impact of the Middle East crisis via inventory management and resources on hand and also leaning on momentum in its US business, with products like generic Ventolin lined up for launch, to drive growth.
Scrip - May 14, 2026
Cipla is cushioning the impact of the Middle East crisis via inventory management and resources on hand and also leaning on momentum in its US business, with products like generic Ventolin lined up for launch, to drive growth.
Scrip - May 14, 2026
Fosun, AriBio’s Alzheimer’s Partnership Expands To Global Markets Via Option Deal
Fosun Pharma moves to expand partnership with AriBio to major global markets for the Korean biotech’s oral Alzheimer's candidate AR100, amid anticipated topline Phase III results in 2026.
Scrip - May 14, 2026
Fosun Pharma moves to expand partnership with AriBio to major global markets for the Korean biotech’s oral Alzheimer's candidate AR100, amid anticipated topline Phase III results in 2026.
Scrip - May 14, 2026
MSD Expands R&D Collabs With Multiple Chinese Firms
MSD leverages its China R&D collaboration platform to discover early R&D programs with high potential from Chinese companies to speed up clinical translation and clinical development.
Scrip - May 14, 2026
MSD leverages its China R&D collaboration platform to discover early R&D programs with high potential from Chinese companies to speed up clinical translation and clinical development.
Scrip - May 14, 2026
Shionogi Eyes Growth From Radicava, Torii Business This Fiscal Year
Japanese firm eyes 40% revenue growth this fiscal year, boosted by acquisitions of Torii and Radicava, despite a big slowdown for its oral COVID-19 antiviral.
Scrip - May 14, 2026
Japanese firm eyes 40% revenue growth this fiscal year, boosted by acquisitions of Torii and Radicava, despite a big slowdown for its oral COVID-19 antiviral.
Scrip - May 14, 2026
Making Robotic Surgery Affordable Is Florida Company’s ‘Mantra’
SS Innovations is confident that the track record of its Mantra robotic system will result in an FDA clearance sometime this year. The company is also seeking the CE mark for Mantra, which has already been cleared for use in 11 countries. The company’s CEO discusses the robotic system.
Medtech Insight - May 14, 2026
SS Innovations is confident that the track record of its Mantra robotic system will result in an FDA clearance sometime this year. The company is also seeking the CE mark for Mantra, which has already been cleared for use in 11 countries. The company’s CEO discusses the robotic system.
Medtech Insight - May 14, 2026
EU Details AI Act Medtech Compromise
New AI Act text mandates the European Commission to reduce regulatory burden, but bottlenecks are still expected.
Medtech Insight - May 14, 2026
New AI Act text mandates the European Commission to reduce regulatory burden, but bottlenecks are still expected.
Medtech Insight - May 14, 2026
FDA Issues Final Guidance For Patient-Matched Orthopedic Surgical Guides
The final guidance sets out testing, documentation and design process expectations for devices shaped from patient imaging to position orthopedic implants but leaves key thresholds for industry to interpret.
Medtech Insight - May 14, 2026
The final guidance sets out testing, documentation and design process expectations for devices shaped from patient imaging to position orthopedic implants but leaves key thresholds for industry to interpret.
Medtech Insight - May 14, 2026
AstraZeneca Joins Pharma’s Agentic AI Race With Three-Year Owkin Deal
Owkin will build custom agents on its K Pro platform to track rival trials, forecast outcomes and scan patents for AstraZeneca — extending a partnership that already produced a BRCA prescreening tool.
Medtech Insight - May 14, 2026
Owkin will build custom agents on its K Pro platform to track rival trials, forecast outcomes and scan patents for AstraZeneca — extending a partnership that already produced a BRCA prescreening tool.
Medtech Insight - May 14, 2026
PCPC Urges FDA On MoCRA, Innovation After Makary Exit
PCPC said it appreciates former FDA Commissioner Marty Makary’s leadership during a ‘pivotal’ time for innovation and looks forward to working with Acting Commissioner Kyle Diamantas.
HBW Insight - May 14, 2026
PCPC said it appreciates former FDA Commissioner Marty Makary’s leadership during a ‘pivotal’ time for innovation and looks forward to working with Acting Commissioner Kyle Diamantas.
HBW Insight - May 14, 2026
Medicare, Medicaid Patients Could Face Higher Costs From Rx-To-OTC Switches
Rx-to-OTC switches could raise out-of-pocket costs for Medicare and Medicaid patients if coverage policies do not adjust accordingly.
HBW Insight - May 14, 2026
Rx-to-OTC switches could raise out-of-pocket costs for Medicare and Medicaid patients if coverage policies do not adjust accordingly.
HBW Insight - May 14, 2026
Karo Builds In APAC With Moberg’s Nail Fungus Innovation
Karo Healthcare has snapped up the exclusive rights to market Moberg Pharma’s topical onychomycosis treatment, MOB-15, under its Lamisil brand in four markets across Asia Pacific.
HBW Insight - May 14, 2026
Karo Healthcare has snapped up the exclusive rights to market Moberg Pharma’s topical onychomycosis treatment, MOB-15, under its Lamisil brand in four markets across Asia Pacific.
HBW Insight - May 14, 2026
Makary Leaves OTC Mark As FDA Commissioner But One Consumer Health Blank Space Resonates
Martin Makary established himself after becoming commissioner in March 2025 as an ally for OTC drug providers by saying on multiple occasions that more drugs should be available nonprescription.
HBW Insight - May 14, 2026
Martin Makary established himself after becoming commissioner in March 2025 as an ally for OTC drug providers by saying on multiple occasions that more drugs should be available nonprescription.
HBW Insight - May 14, 2026
Mylan Epoprostenol Win Clarifies US Measurement Rules And Equivalents Limits
Viatris’ Mylan has prevailed at the Federal Circuit after the court held Actelion’s Veletri formulation claims required pH measurement at standard temperature, while the claims could not be saved through the doctrine of equivalents.
Generics Bulletin - May 14, 2026
Viatris’ Mylan has prevailed at the Federal Circuit after the court held Actelion’s Veletri formulation claims required pH measurement at standard temperature, while the claims could not be saved through the doctrine of equivalents.
Generics Bulletin - May 14, 2026
The Generics Bulletin Podcast: Biosimilars Conference Report And Big M&A Deals
Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, as well as talking about the latest big deals in biosimilars and what is behind them.
Generics Bulletin - May 14, 2026
Generics Bulletin's editorial team discusses the recent Medicines for Europe biosimilars conference, as well as talking about the latest big deals in biosimilars and what is behind them.
Generics Bulletin - May 14, 2026
Medtech’s Hottest Turf War: Why Every Medtech Giant Wants A Piece Of The IVL Market
Intravascular lithotripsy spent years as Shockwave's niche. With J&J's acquisition complete and rivals closing in, the market for cracking arterial calcium is about to get competitive.
In Vivo - May 14, 2026
Intravascular lithotripsy spent years as Shockwave's niche. With J&J's acquisition complete and rivals closing in, the market for cracking arterial calcium is about to get competitive.
In Vivo - May 14, 2026
Dealmaking Quarterly Statistics, Q1 2026
During Q1, biopharma merger and acquisition deal value reached $54bn and drew in $88.7bn in potential deal value from alliances. Device company M&A values reached $27bn, while in vitro diagnostics and research tools players’ M&A activity totaled $986m.
In Vivo - May 14, 2026
During Q1, biopharma merger and acquisition deal value reached $54bn and drew in $88.7bn in potential deal value from alliances. Device company M&A values reached $27bn, while in vitro diagnostics and research tools players’ M&A activity totaled $986m.
In Vivo - May 14, 2026